COVID-19 VACCINES: TARGETS, PRE-CLINICAL STUDIES, MECHANISMS OF ACTION, ADRS, AND ROLLOUT IN INDIA – A JOURNEY SO FAR

DEVESH D GOSAVI; CHETA N SHINDE

doi:10.22159/ajpcr.2022.v15i12.46003

Authors

DEVESH D GOSAVI Department of Pharmacology, Mahatma Gandhi Institute of Medical Sciences, Sewagram, Maharashtra, India. https://orcid.org/0000-0003-3435-1119
CHETA N SHINDE Department of Pharmacology, Mahatma Gandhi Institute of Medical Sciences, Sewagram, Maharashtra, India. https://orcid.org/0000-0002-2842-3748

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i12.46003

Keywords:

COVID vaccines, Adverse effects of COVID vaccines

Abstract

Coronavirus disease 2019 pandemic has been posing a serious threat to global public health till date. This calls for the development of effective treatment protocols, and most importantly, vaccines against the pathogen. Keeping these requirements in mind, we have pooled together, across broad domains of research, accounts on the leading efforts in the development of various vaccine candidates. It is apparent from our review of various studies that the efficacy of seemingly different techniques applied together, collaborative efforts coupled with rapid, timely dissemination of results has been the key behind successful vaccine development. The availability of curated databases has also been of great advantage. Furthermore, we have summarized in this article, the side effects of the various vaccines. We hope that this review will appeal the researchers and students as well as recent entrants in these research domains and the various studies described herein will inspire and be helpful for the advancement of public health.

Downloads

Download data is not yet available.

Author Biography

DEVESH D GOSAVI, Department of Pharmacology, Mahatma Gandhi Institute of Medical Sciences, Sewagram, Maharashtra, India.

PROFESSOR, DEPARTMENT OF PHARMACOLOGY, MGIMS SEWAGRAM

References

Kumar S, Maurya VK, Prasad AK, Bhatt ML, Saxena SK. Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV). Virusdisease 2020;31:13-21. doi: 10.1007/s13337-020-00571-5, PMID 32206694

Ji H, Yan Y, Ding B, Guo W, Brunswick M, Niethammer A, et al. Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus. Med Drug Discov 2020;5:100026. doi: 10.1016/j. medidd.2020.100026, PMID 32289117

Enayatkhani M, Hasaniazad M, Faezi S, Gouklani H, Davoodian P, Ahmadi N, et al. Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: An in silico study. J Biomol Struct Dyn 2021;39:2857-72. doi: 10.1080/07391102.2020.1756411, PMID 32295479

Qiu T, Mao T, Wang Y, Zhou M, Qiu J, Wang J, et al. Identification of potential cross-protective epitope between a new type of coronavirus (2019-nCoV) and severe acute respiratory syndrome virus. J Genet Genomics 2020;47:115-7. doi: 10.1016/j.jgg.2020.01.003, PMID 32171450

Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: Implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol 2020;17:613-20. doi: 10.1038/ s41423-020-0400-4, PMID 32203189

Chen WH, Hotez PJ, Bottazzi ME. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19. Hum Vaccin Immunother 2020;16:1239-42. doi: 10.1080/21645515.2020.1740560, PMID 32298218

Ahmed SF, Quadeer AA, McKay MR. COVIDep: A web-based platform for real-time reporting of vaccine target recommendations for SARS-CoV-2. Nat Protoc 2020;15:2141-2. doi: 10.1038/s41596-020- 0358-9, PMID 32555466

Baruah V, Bose S. Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV. J Med Virol 2020;92:495-500. doi: 10.1002/jmv.25698, PMID 32022276

Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol 2020;20:339-41. doi: 10.1038/s41577-020-0321-6, PMID 32317716

Lucchese G. Epitopes for a 2019-nCoV vaccine. Cell Mol Immunol 2020;17:539-40. doi: 10.1038/s41423-020-0377-z, PMID 32094505

Muñoz-Fontela C, Dowling WE, Funnell SG, Gsell PS, Riveros- Balta AX, Albrecht RA, et al. Animal models for COVID-19. Nature 2020;586:509-15. doi: 10.1038/s41586-020-2787-6, PMID 32967005

Huh D, Torisawa YS, Hamilton GA, Kim HJ, Ingber DE. Microengineered physiological biomimicry: Organs-on-chips. Lab Chip 2012;12:2156-64. doi: 10.1039/c2lc40089h, PMID 22555377

Ramani S, Crawford SE, Blutt SE, Estes MK. Human organoid cultures: Transformative new tools for human virus studies. Curr Opin Virol 2018;29:79-86. doi: 10.1016/j.coviro.2018.04.001, PMID 29656244

Rosellini A, Freer G, Quaranta P, Dovere V, Menichini M, Maggi F, et al. Enhanced in vitro virus expression using 3-dimensional cell culture spheroids for infection. J Virol Methods 2019;265:99-104. doi: 10.1016/j.jviromet.2018.12.017, PMID 30582939

He B, Chen G, Zeng Y. Three-dimensional cell culture models for investigating human viruses. Virol Sin 2016;31:363-79. doi: 10.1007/ s12250-016-3889-z, PMID 27822716

Safronetz D, Geisbert TW, Feldmann H. Animal models for highly pathogenic emerging viruses. Curr Opin Virol 2013;3:205-9. doi: 10.1016/j.coviro.2013.01.001, PMID 23403208

Mestas J, Hughes CC. Of mice and not men: Differences between mouse and human immunology. J Immunol 2004;172:2731-8. doi: 10.4049/jimmunol.172.5.2731, PMID 14978070

Barkauskas CE, Chung MI, Fioret B, Gao X, Katsura H, Hogan BL. Lung organoids: Current uses and future promise. Development 2017;144:986-97. doi: 10.1242/dev.140103, PMID 28292845

Si L, Bai H, Rodas M, Cao W, Oh CY, Jiang A, et al. Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemics. bioRxiv 2020;02115:212-41.

Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: A double-blind, randomised, phase 1 trial. Lancet Infect Dis 2021;21:637-46. doi: 10.1016/S1473-3099(20)30942-7, PMID 33485468

Available from: https://www.mohfw.home

Willis DB, Goorha R, Chinchar VG. Macromolecular synthesis in cells infected by frog virus 3. Curr Top Microbiol Immunol 1985;116:77- 106. doi: 10.1007/978-3-642-70280-8_5, PMID 3893912

Shanmugam S, Venugopal P, Sriram DK, George M. Evaluation of adenoviral vector-based vaccines for prevention of COVID-19- an overview. Asian J Pharm Clin Res 2022;15:6-16. doi: 10.22159/ ajpcr.2022.v15i7.44261

Covid-19 Vaccination in India-vaccinate India. Available from: https:// www.vaccinate-india.in/dashboard [Last accessed on 2022 Feb 11].

CoWIN Dashboard. Available from: https://www.dashboard.cowin. gov.in/[Last accessed on 2022 Feb 11].

Serum Institute gets DCGI’s nod to Manufacture Covid Vaccine Sputnik V in India: Report. Available from: https://www.livemint.com/news/ india/serum-institute-gets-dcgi-s-nod-to-manufacture-covid-vaccine-sputnik-v-in-india-report-11622818500423.html [Last accessed on 2022 Feb 11].

RDIF and Serum Institute of India, the World’s Largest Vaccine Manufacturer by volume, to Start Production of Sputnik Vaccine at Company’s Facilities in September [press release]; 13.07.2021 Russian Direct Investment Fund. Available from: https://www.rdif.ru/Eng_ fullNews/6934/[Last accessed on 2022 Feb 11].

Coronavirus: India Approves Vaccines from Bharat Biotech and Oxford/Astra Zeneca-BBC News. Available from: https://www.bbc. com/news/world-asia-india-55520658 [Last accessed on 2022 Feb 11].

Delhi Reportedly Halts Astra Zeneca Covid Vaccine Exports as Cases Soar India. The Guardian. Available from: https://www.theguardian. com/world/2021/mar/24/delhi-reportedly-halts-astrazeneca-covid-vaccine-exports-as-cases-soar [Last accessed on 2022 Feb 11].

Covid Vaccine: Why did EU take Astra Zeneca to Court?-BBC News. Available from: https://www.bbc.com/news/56483766 [Last accessed on 2022 Feb 11].

Expert Panel Clears Bharat Biotech’s Covaxin amid UK Virus Strain:What you Need to Know Available from: https://www.news18.com/ news/india/expert-panel-clears-bharat-biotechs-covaxin-amid-uk-virus-strain-what-you-need-to-know-3240500.html [Last accessed on 2022 Feb 11].

Coronavirus Vaccine Dilemma-to Take or not to Take Covaxin-the Hindu. Available from: https://www.thehindu.com/sci-tech/health/ vaccine-dilemma-to-take-or-not-to-take-covaxin/article33577223.ece [Last accessed on 2022 Feb 11].

Coronavirus Covaxin Recipients Asked to Sign Consent Form on ’Clinical Trial Mode’-the Hindu. Available from: https://www.thehindu. com/news/national/coronavirus-bharat-biotech-to-pay-compensation-if-covaxin-vaccine-causes-side-effects/article33587377.ece [Last accessed on 2022 Feb 11].

Covid Vaccination for Children in India: Children between 15-18 Years can Register on CoWin from Jan 1, on-site from Jan 3 India news-times of India. Available from: https://www.timesofindia.indiatimes.com/ india/covid-vaccination-children-between-15-18-years-can-register-on-cowin-from-jan-1-on-site-from-jan-3/articleshow/88531760.cms [Last accessed on 2022 Feb 13].

World Health Organization. COVID19 Vaccine Tracker. Geneva: World Health Organization. Available from: https://covid19.trackvaccines. org/agency/who/[Last accessed on 2022 Feb 13].

Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet 2021;398:2173-84. doi: 10.1016/ S0140-6736(21)02000-6, PMID 34774196

Vaccine Information. New Delhi: Indian Council of Medical Research- COVID-19 Vaccine. Available from: https://www.vaccine.icmr.org.in/ covid-19-vaccine [Last accessed on 2022 Feb 13].

Misra SK, Pathak K, Pathak D, Yadav R. Current updates on Covid-19 vaccines. Asian J Pharm Clin Res 2021;14:17-23. doi: 10.22159/ ajpcr.2021.v14i5.41061

Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates. NPJ Vaccines 2021;6:28.

Arya SC, Agarwal N. Apropos risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. Expert Rev Vaccines 2012;11:1291. doi: 10.1586/erv.12.110, PMID 23249227

What are the Side Effects of COVID-19 Vaccines, and Should you Worry? Available from: https://www.medicalnewstoday.com/articles/ global-covid-19-vaccine-summary-side-effects#Potential-side-effects-per-vaccine [Last accessed on 2022 Feb 16].

Hasselbach L, Voß A. Thrombotic thrombocytopenic purpura after COVID-19 vaccination: A case report. Arch Clin Biomed Res 2021;5:737-41. doi: 10.26502/acbr.50170198

Nyayakar S, Srinivasan R, Archana L, Nithyanandan S. A cross-sectional study on acceptance and post-vaccination symptoms of Covid-19 vaccination in India. Asian J Pharm Clin Res 2022;15:107- 10. doi: 10.22159/ajpcr.2022.v15i1.43158

Centers for Disease Control and Prevention. Possible Side Effects after Getting a COVID-19 vaccine. CDC. Georgia, United States: Centers for Disease Control and Prevention.

Coronavirus Disease (COVID-19): Vaccines Safety. Available from: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines-safety [Last accessed on 2022 Feb 17].

Shimabukuro T. Thrombosis with Thrombocytopenia Syndrome (TTS) following Janssen COVID-19 Vaccine Advisory Committee on Immunization PrSactices (ACIP). CDC COVID-19 Vaccine Task Force Vaccine Safety Team. Atlanta, Georgia: Advisory Committee on Immunization Practices; 2021.

Norway should exclude J&J, Astra Zeneca from vaccine scheme-panel. Reuters. Available from: https://www.reuters.com/world/europe/ norway-should-exclude-jj-astrazeneca-covid-vaccination-scheme-says-commission-2021-05-10/[Last accessed on 2022 Feb 17].

Flaherty L. Department of health and human services. J Emerg Nurs 2000;26:242-6. doi: 10.1016/S0099-1767(00)90099-0.

Guillain-Barré syndrome: Symptoms, Causes, Diagnosis, and Treatment. Available from: https://www.medicalnewstoday.com/ articles/167892 [Last accessed on 2022 Feb 17].

Meeting Highlights from the Pharmacovigilance Risk Assessment Committee (PRAC). South Amsterdam: European Medicines Agency. Available from: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8- july-2021 [Last accessed on 2022 Feb 17].

COVID-19 Vaccine Astra Zeneca: PRAC Investigating Cases of Thromboembolic events-vaccine’s Benefits Currently Still Outweigh risks-Update. South Amsterdam: European Medicines Agency. Available from: https://www.ema.europa.eu/en/news/covid-19- vaccine-astrazeneca-prac-investigating-cases-thromboembolic-events-vaccines-benefits [Last accessed on 2022 Feb 17].

Astra Zeneca’s COVID-19 vaccine: EMA Finds Possible Link to Very Rare Cases of Unusual Blood Clots with Low Blood Platelets. South Amsterdam: European Medicines Agency. Available from: https:// www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood [Last accessed on 2022 Feb 17].

Oxford-Astra Zeneca: EU says ’No Indication’ Vaccine Linked to Clots-BBC News. Available from: https://www.bbc.com/news/world-europe-56357760 [Last accessed on 2022 Feb 17].

In world first, Denmark ditches Astra Zeneca’s COVID-19 shot. Reuters. Available from: https://www.reuters.com/world/europe/world-first-denmark-ditches-astrazenecas-covid-19-shot-2021-04-14/[Last accessed on 2022 Feb 17].

Britain. Germany in role reversal on Astra Zeneca vaccine risks. Available from: https://www.reuters.com/world/europe/third-wave-pandemic-appears-be-broken-german-health-minister-2021-05-07/ [Last accessed on 2022 Feb 17].

I don’t want that. Reuters. France Struggles to Pitch AstraZeneca Vaccine. Available from: https://www.reuters.com/world/europe/i-dont-want-that-france-struggles-pitch-astrazeneca-vaccine-2021-04-19 [Last accessed on 2022 Feb 17].

EU has not Ordered Astra Zeneca Vaccines Beyond June-commissioner. Canary Wharf, London: Reuters. Available from: https://www.reuters. com/world/europe/eus-breton-eu-did-not-renew-astrazeneca-covid-19- vaccine-order-after-june-2021-05-09 [Last accessed on 2022 Feb 17].

Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med 2021;385:1172-83. doi: 10.1056/NEJMoa2107659, PMID 34192426